What is the BRCA Mutation Rate in Ashkenazi Jews?
At a Glance
The prevalence of BRCA mutations in the Ashkenazi Jewish population is about 1 in 40 (2.5%), which is significantly higher than the 1 in 400 rate in the general population. This high rate is caused by the founder effect and involves three specific genetic mutations.
In this answer
3 sections
If you have any Ashkenazi Jewish ancestry, you are significantly more likely to carry a mutation in the BRCA1 or BRCA2 genes than people in the general population [1]. About 1 in 40 individuals of Ashkenazi Jewish descent carries a BRCA mutation (approximately 2.5%), compared to about 1 in 400 people in the general population [1].
This difference is due to population genetics and a phenomenon known as the founder effect.
Understanding the Founder Effect
The founder effect happens when a small group of individuals separates from a larger population to establish a new, isolated community [2][3]. If even a few individuals in that original “founding” group happen to carry a specific genetic mutation, that mutation can become much more common as the population grows over generations, because they generally marry and have children within their own community [2].
For the Ashkenazi Jewish population, historical events led to a smaller ancestral group that grew rapidly over centuries. As a result, certain genetic traits—including specific changes in the BRCA1 and BRCA2 genes—became concentrated and are seen at much higher rates today [3].
The Three Founder Mutations
In the Ashkenazi Jewish population, almost all BRCA mutations involve just three specific genetic changes, collectively known as the founder mutations [1]:
- 185delAG (in the BRCA1 gene)
- 5382insC (in the BRCA1 gene)
- 6174delT (in the BRCA2 gene)
(Note: You may see these listed differently on modern lab results, such as c.68_69delAG instead of 185delAG).
These three specific mutations account for the majority of hereditary breast and ovarian cancers in families of Ashkenazi descent [1].
What This Means for Testing and Cancer Risk
The presence of any of these mutations significantly increases a person’s lifetime risk of developing certain cancers. The risk depends on which specific gene is affected:
- Breast cancer: By age 80, the risk is about 72% for BRCA1 carriers and 69% for BRCA2 carriers [4].
- Ovarian cancer: By age 80, the risk is approximately 44% for BRCA1 carriers and 17% for BRCA2 carriers [4].
- Other cancers: Prostate cancer, pancreatic cancer, and male breast cancer are also linked to these genes. For instance, BRCA2 mutations are associated with a particularly higher risk of aggressive prostate cancer compared to BRCA1 [4].
While these numbers can be intimidating, knowing your mutation status is highly empowering. Identifying a mutation before cancer develops allows you and your care team to take proactive steps, such as starting enhanced screenings (like breast MRIs) at an earlier age, discussing risk-reducing surgeries, or individualizing how a detected cancer is managed [5].
Because these specific mutations are so well understood, genetic testing for individuals with Ashkenazi Jewish heritage often begins by looking specifically for these three variants [2]. However, it is also important to note that individuals of Ashkenazi descent can occasionally carry other, non-founder mutations in BRCA1, BRCA2, or other cancer susceptibility genes [6][7]. For this reason, doctors or genetic counselors may sometimes recommend a more comprehensive multigene panel rather than just checking for the three founder mutations [6].
Common questions in this guide
Why are BRCA mutations more common in people of Ashkenazi Jewish descent?
What are the three BRCA founder mutations?
Should I get tested for just the three founder mutations or a multigene panel?
If I test negative for the founder mutations, does that mean I am not at risk for cancer?
Should men in my family be tested for BRCA mutations?
Related questions
Show more
Get notified when new evidence is published on Hereditary breast and/or ovarian cancer syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing JP, Hartge P, Wacholder S, et al.
The New England journal of medicine 1997; (336(20)):1401-8 doi:10.1056/NEJM199705153362001.
PMID: 9145676 - 2
The role of BRCA1/2 in hereditary and familial breast and ovarian cancers.
Hawsawi YM, Al-Numair NS, Sobahy TM, et al.
Molecular genetics & genomic medicine 2019; (7(9)):e879 doi:10.1002/mgg3.879.
PMID: 31317679 - 3
Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
Yurgelun MB, Hiller E, Garber JE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(28)):3092-5 doi:10.1200/JCO.2015.60.8596.
PMID: 26282646 - 4
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al.
JAMA 2017; (317(23)):2402-2416 doi:10.1001/jama.2017.7112.
PMID: 28632866 - 5
Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Hemal S, DeWitt-Foy M, Klein EA
Urology 2021; (153()):129-131 doi:10.1016/j.urology.2020.11.076.
PMID: 33556450 - 6
Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK, Sandler G, Sobolev R, et al.
Gynecologic oncology 2017; (146(1)):123-128 doi:10.1016/j.ygyno.2017.04.009.
PMID: 28495237 - 7
Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.
Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, et al.
Breast cancer research and treatment 2016; (155(1)):133-8 doi:10.1007/s10549-015-3662-2.
PMID: 26687385
This page is for informational purposes only and does not replace professional medical advice. Always consult a genetic counselor or healthcare provider about genetic testing and your personal cancer risk.